FAST - A prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating long term cardiovascular safety of febuxostat in comparison with allopurinol in patients with chronic symptomatic hyperuricaemia.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Gout
- Focus Adverse reactions
- Acronyms FAST
- 08 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2017 This trial has been Discontinued in Finland , according to European Clinical Trials Database.
- 04 Dec 2015 Accrual to date is 41% as reported by the United Kingdom Clinical Research record.